Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Aug;80(12):2025–2033. doi: 10.1038/sj.bjc.6690637

Investigation of female survival benefit in metastatic melanoma

B Richardson 1, A Price 2, M Wagner 1, V Williams 1, P Lorigan 4, S Browne 4, J G Miller 3, S Mac Neil 1
PMCID: PMC2363135  PMID: 10471056

Abstract

Epidemiological studies show female survival benefit in advanced metastatic melanoma. In investigating a possible mechanism for this female survival benefit, we have previously reported that the female steroid 17β-oestradiol significantly reduces invasion of a human melanoma cell line (A375-SM cells) and ocular melanoma cells through fibronectin. Neither cell type was found to possess oestrogen receptor-α. The aim of the current study was to obtain further information on the extent to which progression of cutaneous melanoma might be sex steroid sensitive by (a) examining the relationship between circulating sex steroids, sex hormone binding globulin and disease progression; (b) examining the relationship between sex steroid structure and the ability of steroids to reduce invasion of a melanoma cell line in vitro; and (c) examining the effects of sex steroids on proliferation of these cells in vitro. We report a significant reduction in circulating oestrone with disease progression in male but not female patients. Examining steroids for their ability to inhibit invasion of A375-SM cells through fibronectin in vitro, oestrogenic compounds (17β-oestradiol and oestrone) were found to inhibit invasion; in this respect, oestrone was approximately 50 times more potent than 17β-oestradiol; steroids lacking the benzene ring structure did not inhibit invasion, indeed dehydroepiandrosterone (DHEA) which acts as a precursor to androgenic steroids significantly enhanced invasion. Proliferation of A375-SM cells was unaffected by 17β-oestradiol, oestrone or dihydrotestosterone when cells were cultured on plastic; in contrast, all three steroids induced modest proliferation of cells when grown on fibronectin with dihydrotestosterone the most mitogenic of the three steroids. These data are consistent with sex steroids playing a role in melanoma progression. © 1999 Cancer Research Campaign

Keywords: melanoma, invasion, oestrogen, testosterone, oestrogen receptor-β

Full Text

The Full Text of this article is available as a PDF (116.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brandenberger A. W., Tee M. K., Lee J. Y., Chao V., Jaffe R. B. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab. 1997 Oct;82(10):3509–3512. doi: 10.1210/jcem.82.10.4400. [DOI] [PubMed] [Google Scholar]
  2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970 Nov;172(5):902–908. doi: 10.1097/00000658-197011000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cocconi G., Bella M., Calabresi F., Tonato M., Canaletti R., Boni C., Buzzi F., Ceci G., Corgna E., Costa P. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992 Aug 20;327(8):516–523. doi: 10.1056/NEJM199208203270803. [DOI] [PubMed] [Google Scholar]
  4. Cuzick J., Allen D., Baum M., Barrett J., Clark G., Kakkar V., Melissari E., Moniz C., Moore J., Parsons V. Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur J Cancer. 1992;29A(1):15–21. doi: 10.1016/0959-8049(93)90568-z. [DOI] [PubMed] [Google Scholar]
  5. Daffada A. A., Johnston S. R., Smith I. E., Detre S., King N., Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res. 1995 Jan 15;55(2):288–293. [PubMed] [Google Scholar]
  6. De Ryck L. M., Ross J. B., Petra P. H., Gurpide E. Estradiol entry into endometrial cells in suspension. J Steroid Biochem. 1985 Aug;23(2):145–152. doi: 10.1016/0022-4731(85)90229-8. [DOI] [PubMed] [Google Scholar]
  7. Dewhurst L. O., Gee J. W., Rennie I. G., MacNeil S. Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br J Cancer. 1997;75(6):860–868. doi: 10.1038/bjc.1997.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Duncan L. M., Travers R. L., Koerner F. C., Mihm M. C., Jr, Sober A. J. Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: absence of immunohistochemically detectable hormone receptors. Hum Pathol. 1994 Jan;25(1):36–41. doi: 10.1016/0046-8177(94)90168-6. [DOI] [PubMed] [Google Scholar]
  9. Edward M., Grant A. W., Mackie R. M. Human melanoma cell-derived factor(s) stimulate fibroblast glycosaminoglycan synthesis. Int J Cancer. 1992 Sep 30;52(3):499–503. doi: 10.1002/ijc.2910520327. [DOI] [PubMed] [Google Scholar]
  10. Feucht K. A., Walker M. J., Das Gupta T. K., Beattie C. W. Effect of 17 beta-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice. Cancer Res. 1988 Dec 15;48(24 Pt 1):7093–7101. [PubMed] [Google Scholar]
  11. Gefeller O., Hassan K., Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol. 1998 Jan;138(1):122–124. doi: 10.1046/j.1365-2133.1998.02037.x. [DOI] [PubMed] [Google Scholar]
  12. Jordan V. C., Fritz N. F., Tormey D. C. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res. 1987 Aug 15;47(16):4517–4519. [PubMed] [Google Scholar]
  13. Karjalainen S., Hakulinen T. Survival and prognostic factors of patients with skin melanoma. A regression-model analysis based on nationwide cancer registry data. Cancer. 1988 Nov 15;62(10):2274–2280. doi: 10.1002/1097-0142(19881115)62:10<2274::aid-cncr2820621034>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  14. Ladányi A., Tímár J., Bocsi J., Tóvári J., Lapis K. Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res. 1995 Apr;5(2):83–86. doi: 10.1097/00008390-199504000-00002. [DOI] [PubMed] [Google Scholar]
  15. Luqmani Y. A., Smith J., Coombes R. C. Polymerase chain reaction-aided analysis of gene expression in frozen tissue sections. Anal Biochem. 1992 Feb 1;200(2):291–295. doi: 10.1016/0003-2697(92)90468-m. [DOI] [PubMed] [Google Scholar]
  16. Mac Neil S., Wagner M., Kirkham P. R., Blankson E. A., Lennard M. S., Goodall T., Rennie I. G. Inhibition of melanoma cell/matrix interaction by tamoxifen. Melanoma Res. 1993 Feb;3(1):67–74. doi: 10.1097/00008390-199304000-00010. [DOI] [PubMed] [Google Scholar]
  17. Miller J. G., Gee J., Price A., Garbe C., Wagner M., Mac Neil S. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Res. 1997 Jun;7(3):197–208. doi: 10.1097/00008390-199706000-00003. [DOI] [PubMed] [Google Scholar]
  18. Miller J. G., Mac Neil S. Gender and cutaneous melanoma. Br J Dermatol. 1997 May;136(5):657–665. [PubMed] [Google Scholar]
  19. Morvillo V., Luthy I. A., Bravo A. I., Capurro M. I., Donaldson M., Quintans C., Calandra R. S., Mordoh J. Atypical androgen receptor in the human melanoma cell line IIB-MEL-J. Pigment Cell Res. 1995 Jun;8(3):135–141. doi: 10.1111/j.1600-0749.1995.tb00654.x. [DOI] [PubMed] [Google Scholar]
  20. O'Bryan J. P., Frye R. A., Cogswell P. C., Neubauer A., Kitch B., Prokop C., Espinosa R., 3rd, Le Beau M. M., Earp H. S., Liu E. T. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991 Oct;11(10):5016–5031. doi: 10.1128/mcb.11.10.5016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Petra P. H. The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol. 1991;40(4-6):735–753. doi: 10.1016/0960-0760(91)90299-k. [DOI] [PubMed] [Google Scholar]
  22. Rosner W., Hryb D. J., Khan M. S., Nakhla A. M., Romas N. A. Sex hormone-binding globulin: anatomy and physiology of a new regulatory system. J Steroid Biochem Mol Biol. 1991;40(4-6):813–820. doi: 10.1016/0960-0760(91)90307-q. [DOI] [PubMed] [Google Scholar]
  23. Shaw H. M., McGovern V. J., Milton G. W., Farago G. A., McCarthy W. H. Malignant melanoma: influence of site of lesion and age of patient in the female superiority in survival. Cancer. 1980 Dec 15;46(12):2731–2735. doi: 10.1002/1097-0142(19801215)46:12<2731::aid-cncr2820461232>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  24. Shaw H. M., Milton G. W., Farago G., McCarthy W. H. Endocrine influences on survival from malignant melanoma. Cancer. 1978 Aug;42(2):669–677. doi: 10.1002/1097-0142(197808)42:2<669::aid-cncr2820420238>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  25. Slingluff C. L., Jr, Seigler H. F. Malignant melanoma and pregnancy. Ann Plast Surg. 1992 Jan;28(1):95–99. doi: 10.1097/00000637-199201000-00024. [DOI] [PubMed] [Google Scholar]
  26. Stidham K. R., Johnson J. L., Seigler H. F. Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg. 1994 Mar;129(3):316–324. doi: 10.1001/archsurg.1994.01420270094020. [DOI] [PubMed] [Google Scholar]
  27. Travers R. L., Sober A. J., Berwick M., Mihm M. C., Jr, Barnhill R. L., Duncan L. M. Increased thickness of pregnancy-associated melanoma. Br J Dermatol. 1995 Jun;132(6):876–883. doi: 10.1111/j.1365-2133.1995.tb16942.x. [DOI] [PubMed] [Google Scholar]
  28. Vladusic E. A., Hornby A. E., Guerra-Vladusic F. K., Lupu R. Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res. 1998 Jan 15;58(2):210–214. [PubMed] [Google Scholar]
  29. Wheeler M. J., D'Souza A., Matadeen J., Croos P. Ciba Corning ACS:180 testosterone assay evaluated. Clin Chem. 1996 Sep;42(9):1445–1449. [PubMed] [Google Scholar]
  30. Wians F. H., Jr, Stuart J. Ciba Corning ACS:180 direct total testosterone assay can be used on female sera. Clin Chem. 1997 Aug;43(8 Pt 1):1466–1468. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES